Kiniksa whiffs on efficacy trying to repurpose an RA program for Covid-19, but spins survival 'trends' as a positive
As the search for more potential Covid-19 treatments continues, Kiniksa Pharmaceuticals $KNSA has revealed data for a repurposed immunology candidate it says are positive. But the numbers paint a much murkier picture.
The Bermuda-based biotech whiffed badly on the primary endpoint in the small Phase II portion of a Phase II/III study for its mavrilimumab program, saying that after two weeks the proportion of patients with severe Covid-19 who were alive and off supplemental oxygen was not statistically significant compared to placebo. Kiniksa also missed the secondary endpoint — proportion of patients alive and without respiratory failure after four weeks — though it noted the data moved in the right direction over longer periods.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.